Hima Vyshnavi A. M.

Hima Vyshnavi A. M.

Auto-generated profile, based on publicly available information

Hima Vyshnavi A. M.

Computational Chemistry Group (CCG), Amrita Molecular Modeling And Synthesis Research Lab, Amrita School of Engineering, Coimbatore, Amrita Vishwa Vidyapeetham, India, 641112

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2018
Verified
Conference Paper
Closed access
AIAkshay Iyer
Akshay Iyer
HMHima Vyshnavi A M
Hima Vyshnavi A M
KKKrishnan Namboori P K
Krishnan Namboori P K
The recently introduced deep learning environment has been used in post pharmacogenomic predictions on proneness to lung cancer. The well-established pre-trained model, VGG19 has been used to extract information from the pathological images specific to PTEN, EGFR, ERBB2, BRAF and CDKN2A for Lung cancer. The model finds to be suitable for the prediction of these mutations, specific to Indian populations. A model consisting of testing of specific genetic signatures and the deep convolution network based image classification has been suggested as an ingenious technique for the fast, cheap and effective predictions on mutations of lung cancer among Indian populations.

10 January 2017 in Journal of Young Pharmacists
Verified
Journal Article
Open access
HMHimaVyshnavi A M
HimaVyshnavi A M
LCLakshmi Anand C
Lakshmi Anand C
DMDeepak O M
Deepak O M
KKKrishnan Namboori P K
Krishnan Namboori P K

1 March 2019
Verified
Conference Paper
Closed access
ASAkshayaa S.
Akshayaa S.
VRVidhya R.
Vidhya R.
HAHima Vyshnavi A.M.
Hima Vyshnavi A.M.
KPKrishnan Namboori P.K.
Krishnan Namboori P.K.
Chronic pain is one of the major health issues which affects wellbeing of casualties ranging from orthopedic damages to unbearable cancer pain. Though analgesics aids in reducing pain sensitization, it has its own defect of causing side effects such as drug resistance and habit formation. Evolutionary research has evidenced that by mutating "ZFHX2" gene, one can achieve pain insensitivity. This work emphases on 1) Designing an early mutation detection tool to identify the presence of pain inducing gene ZFHX2 among various patients from pathological biopsy images using deep convolution neural network. 2) Pharmacogenomic analysis comprising of genomics, epigenomics, metagenomics, environmental genomics has been performed in ZFHX2 gene to identify genetic signature, one of the reasons behind causing chronic pain. 3) Block chain algorithm has been used to secure valuable patient clinical data obtained from pharmacogenomic and other analysis to maintain records in order to avoid clinical theft.

7 May 2022 in International Journal of Applied Pharmaceutics
Verified
Journal Article
Open access
PDF file
HMHima Vyshnavi A. M.
Hima Vyshnavi A. M.
KKKrishnan Namboori P K
Krishnan Namboori P K
Objective: The proneness of disease, as well as drug action and side effects, vary from person to person. This may be due to individual variations in the genome. The individual variation demands the need to design a population-specific 'predictive, preventive, participatory and personalized (p4)' pharmacogenomics drug molecule. The present work aims at designing a pharmacogenomic model for breast cancer to explain the individual variation in the proneness of the diseases and susceptibility towards drug action. Methods: The drug action and side effects of drugs were analyzed from clinical trial reports. The genes responsible for the drug action and the genes responsible for side effects have been identified and included in the variation analysis. The pharmacogenomic gene models have been designed by inducing population-specific genetic variations within the gene sequence. The 3D structures of the 'variation-specific' protein models have been generated by 'homology modelling.' These models have been used further for docking studies with the known drug molecules. The kinetic stability of the protein-ligand complexes obtained out of docking studies has been studied by the molecular dynamic simulation. Results: By the interaction studies and the computational analysis using the 'population-specific protein models,' the drug molecule, Capecitabine showed the highest binding affinity (–6.30kcal/mol) with the African population, Paclitaxel was found to be the most interacting with the European population with a binding affinity of–9.5603 kcal/mol, and Lapatinib is found to be the most suitable ligand for the American population with a binding affinity of–6.90 kcal/mol. These observations agree with the clinical trial data found in the 'ClinTrial database'. Conclusion: The designed models are found to be suitable for representing the respective population-specific target models. The interaction studies of known drug molecules with these population-specific target models correspond to the observations in the 'ClinTrial database.'